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Summary The presence of tumour cells in the circulation may predict disease recurrence and metastasis. To improve on existing methods of
cytological or immunocytological detection, we have developed a sensitive and quantitative technique for the detection of carcinoma cells in
blood, using the reverse transcriptase polymerase chain reaction (RT-PCR) identifying transcripts of the pancarcinoma-associated tumour
marker EGP-2 (KSA or 17-lA antigen). The amount of EGP2 mRNA was quantified using an internal recombinant competitor RNA standard
with known concentration and which is both reversely transcribed and co-amplified in the same reaction, allowing for a reliable assessment of
the initial amount of EGP2 mRNA in the sample. Calibration studies, seeding blood with MCF-7 breast carcinoma cells, showed thatthe assay
can detect ten tumour cells among 1.0 x 106 leucocytes. The PCR assay revealed that normal bone marrow expresses low levels of EGP2
mRNA, although immunocytochemistry with the anti-EGP2 MAb MOC31 could not identify any positively stained cell. Analyses using this
RT-PCR assay may prove to have applications to the assessment of circulating tumour cells in clinical samples.
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Despite recent advances in cancer treatment, late metastatic
disease continues to be a major problem in clinical management of
malignancies, such as colorectal, lung, breast, and prostate carci-
noma. Adjuvant therapy to reduce the risk of late recurrences
appears to be beneficial in both breast and colorectal carcinoma
(Fisher et al, 1989; Moertel et al, 1990). The detection of occult
tumour cells in the peripheral blood ofpatients with solid tumours
may be important in two different clinical situations. First, the
finding of circulating tumour cells at diagnosis in patients with
clinically localized disease responsive to chemotherapy, such as
breast or colon cancer, might aid in the choice of adjuvant treat-
ment options. Second, in the setting of autologous bone marrow
transplantation (ABMT) or peripheral stem cell reinfusion after
high-dose chemotherapy, contamination of the reinfused bone
marrow or stem cell population with tumour cells might worsen
prognosis (Anderson et al, 1989; Gribben et al, 1991; Brenner et
al, 1993; Brugger et al, 1994; Moss et al, 1994). In recent years,
especially in breast and colon cancer, it has been shown that occult
contamination ofthe peripheral blood orbone marrow at diagnosis
with tumour cells exerts an adverse influence on survival (Berger
et al, 1988; Cote et al, 1991; Schlimok et al, 1991; Pantel et al,
1993; Diel et al, 1994; Harbeck et al, 1994; Menard et al, 1994).
Often, in these studies, a monoclonal antibody (MAb) or a panel of
MAbs directed against tumour cell-surface glycoproteins or cyto-
keratins was used to detect circulating tumour cells. The develop-
ment ofpolymerase chain reaction (PCR)-based assays may allow
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a more sensitive tumour cell detection. Such assays have been
described for a number of solid and haematological malignancies.
EGP2 (also known as hEGP314, GA733-2 antigen, KSA, EGP40)
is a 38-kDa transmembrane glycoprotein expressed on the surface
ofmost simple epithelial cells and the majority ofcarcinomas such
as colorectal, lung and breast carcinomas (de Leij et al, 1994).
MAbs directed against EGP-2, such as C017-lA, KS1/4 and
MOC31, have been studied extensively in diagnostic and thera-
peutic approaches in cancer (Lobuglio et al, 1986; Elias et al,
1990; Kroesen et al, 1993; Herlyn et al, 1994; Kosterink et al,
1995). The human EGP2 cDNA was independently cloned by
different research groups (Bumol et al, 1988; Strnad et al, 1989;
Szala et al, 1990) and, more recently, its gene structure on chromo-
some 4q has been partly determined. Comparison of GA733-2
gene sequences with the previously established cDNA sequence
revealed that this gene consists of nine exons interspersed by
introns of variable length (Linnenbach et al, 1993).
In this report we describe the detection and quantitative analysis
of very low amounts of EGP2 mRNA transcripts in bone marrow
and peripheral blood by reverse transcriptase PCR (RT-PCR).
MATERIALS AND METHODS
Cell lines
The human small-cell lung cancer (SCLC) cell lines GLC-3, GLC-
4 and GLC-14, the human breast carcinoma cell line MCF-7 and
the human colorectal cancer cell line Colo 320 were selected as
representatives of different types of carcinomas. SCLC cell lines
GLC-3, GLC-4 and GLC-14 were chosen because of the different
expression levels of EGP2 as determined by immunocytochem-
istry. All SCLC cell lines have been established in our laboratory
and have been described previously (de Leij et al, 1985; Zijlstra et
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Figure 1 (A) Schematic representation of the human EGP2 gene. Shown are location of intron (-) and exon (r) sequences (adapted from Linnenbach et al) as
well as the PCR (FW and REV) primers (solid arrows). Diagram is not to scale. (B) The construction of the EGP2 competitor RNA expression plasmid. A 198-bp
BamHl fragment was removed from plasmid CDM8EGP2 by digestion with BamHl and subsequent plasmid religation yielding CDM8EGP2-B. Recombinant
RNA was transcribed in vitro from the T7 promoter (open arrows). Amplification with the FW and REV primers gives rise to a product of 514 bp for normal EGP2
mRNA and 316 bp when using the recombinant competitor EGP2-B mRNA (solid bars). When genomic DNA is amplified no signal can be obtained, as the PCR
primers span the EGP2 intron numbers to 3-6, constituting a DNA sequence of over 5 kb (see 1A). The restriction enzyme sites BamHl and Scal are indicated
by B and S respectively. 0, Start codon; *, Stop codon
al, 1987; Berendsen et al, 1988). The MCF-7 and Colo 320 cell
lines were obtained from the American Type Culture Collection
(cat. nos HTB-22, CCL-220; ATCC Rockville, MD, USA). All
cell lines were maintained in RPMI-1640 medium supplemented
with 10% FCS, 5 x 10-5 M ,B-mercaptoethanol and 1 mm sodium
pyruvate, in a humidified 5% carbon dioxide atmosphere at 37°C.
Collection of blood samples
Blood samples were taken from seven healthy volunteers after
obtaining informed consent. All samples were collected in
heparinized tubes on ice. In order to avoid contamination ofblood
cells with cells originating from the skin, which may contain some
glandular cells expressing EGP2, at least two samples were drawn,
of which the first was discarded.
Bone marrow and peripheral stem cell harvests
Bone marrow was obtained from one of the seven healthy volun-
teers by aspiration. Additionally, bone marrow aspirates from
three patients suffering from various haematological malignancies
(chronic myelogenous and acute myelogenous leukaemias) were
analysed. These bone marrow samples were chosen as a model for
normal bone marrow as they are known to be negative for EGP2 in
immunocytochemistry. Peripheral stem cell harvests from another
three patients with haematological malignancies were collected.
Again, these were chosen as a model for normal samples, i.e. not
containing carcinoma cells.
Immunocytochemistry
Cytocentrifuge slides of acetone-fixed cells were evaluated for
EGP2 expression by incubation with the anti-EGP2 MAb MOC31
and subsequent indirect immunoperoxidase staining, according to
standard procedures (Harlow and Lane, 1988). Endogenous perox-
idase activity present in bone marrow and peripheral blood cells
was inactivated by incubating the slides with 0.3% hydrogen
peroxide for 5 min, after which the slides were rinsed three times
with phosphate-buffered saline (9.0 mm disodium hydrogen phos-
phate, 1.3 mm sodium dihydrogen phosphate, 140 mm sodium
chloride, pH 7.2) (PBS). Peroxidase-conjugated rabbit anti-mouse
immunoglobulins were obtained from Dako (Glostrup, Denmark).
RNA isolation
Large-scale isolation of total cellular RNA from cell lines was
performed using the guanidine isothiocyanate-caesium chloride
method (Chirgwin et al, 1979). Total cellular RNA from leuco-
cytes and bone marrow was isolated using a modified acid
phenol-guanidinium isothiocyanate method; peripheral blood
was centrifuged for 10 min at 900 g and 4°C, and the plasma
was removed. All subsequent steps were performed on ice and
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Figure 2 Principle of the transcript titration assay. The assay is based on the fact that a mixture of two different EGP2 RNA templates, the normal EGP2 mRNA
and the shorter 198-bp EGP2-B RNA, will compete for the same primers. Thus, when both RNA templates are present in a RT-PCR reaction mixture in
equimolar amounts, they will be reversely transcribed and amplified accordingly. A titration series of competitor RAN solutions, decreasing in concentration, is
mixed with a fixed amount of total cellular RNA containing the EGP2 mRNA to be quantified. After RT-PCR all subsequent reaction products of the titration
series were analysed by gel electrophoresis. The relative intensity of the bands (514 bp vs 316 bp) per lane in determined by densitometric scanning. Lane 3
showing a relative intensity ratio of 1:1 for both bands is used to quantify the initial amout of EGP2 mRNA in the sample
prechilled solutions were used. Erythrocytes were removed by
lysis with ammonium chloride (155 mm ammonium chloride,
10 mM potassium bicarbonate, 0.1 mm sodium EDTA). Leucocytes
were pelleted by centrifugation and washed with PBS. The cells
were resuspended in 1 ml ofPBS and counted. The cell suspension
was transferred to a fresh microfuge tube, after which the cells
were pelleted by centrifugation for 10 min at 900g. The cell pellet
was dissolved in 500 pl ofGITC (4 M guanidinium-isothiocyanate,
25 mm sodium citrate pH 7, 0.5% sarcosyl, 0.1 M P-mercapto-
ethanol) by vigorous vortexing. Subsequently, 50 ,l of sodium
acetate (3 M, pH 5.0), 500 gl of water-saturated phenol and 100 pl
of chloroform-isoamyl alcohol (49:1, v/v) were added and mixed
well by vortexing. The mixture was left on ice for 10 min, after
which it was centrifugated at 15 000 g and 4°C. The supernatant
was transferred to a fresh microfuge tube, and precipitated by
adding an equal volume ofisopropanol and placing it at -20°C for
1 h. RNA was pelleted by centrifugation at 15 000 g and 4°C, and
reprecipitated in 150 gl of GITC and isopropanol. RNA was
pelleted by centrifugation as described above, and washed with
70% ethanol. The pellet was dried in a vacuum exicator and
dissolved in 30 gl of diethylpyrocarbonate-treated water (DEPC,
Sigma, St Louis, MO, USA). The integrity of the RNA samples
was assessed on formaldehyde-containing (2.2 M) agarose gels.
Only RNA samples with visible and discrete 28S and 18S ribo-
somal RNA bands were used for the RT-PCR experiments.
Design of the EGP2 RT-PCR
The human EGP-2 gene consists of nine exons interspersed by
introns of variable length (Szala et al, 1990). EGP2-specific PCR
primers were computer designed to span three introns and were
subsequently synthesized using a commercial oligonucleotide
synthesizer (Gene Assembler plus, Pharmacia, Uppsala, Sweden).
The sequences of the EGP2-specific primers are: forward (FW):
5'-GAACAATGATGGGCT'ITATG-3' (corresponding to bases
374 to 394 of the EGP2 cDNA) and reverse (REV): 5'-
TGAGAATTCAGGTGCTTTIT-3' (bases 868-888). Amplification
of EGP2 cDNA with these primers gives rise to a 514-bp product.
When genomic DNA is amplified, no signal is obtained as the PCR
primers span the EGP2 intron numbers 3-6, constituting a DNA
sequence of at least 5 kb. A schematic representation of the human
EGP2 gene (GA733-2) with location of the introns and exons, as
weli as the PCR (FW and REV) primers, is given in Figure IA.
Construction of an EGP2 competitor RNA expression
plasmid
DNA manipulations were performed essentially according to
Sambrook et al (1989). Theplasmid CDM8 EGP2, encompassing the
entire EGP2 cDNA, was a kind gift from DrLinnenbach, The Wistar
Institute, Philadelphia, PA and is described by Szala et al (1990). A
'deletion' competitorEGP2 cDNA construct wasgenerated from this
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Figure 3 Quantitative analysis using the EGP2 RT-PCR. A titration series of
competitor RNA solutions was mixed with 100 ng of total cellular RNA
derived from the EGP2-positive cell line MCF-7. Shown are the subsequent
RT-PCR reaction products after gel electrophoresis/ethidium bromide
staining. Lane M, DNA molecular weight marker VI (Boehtinger Mannheim) -
the upper band represents 653 bp; lane 1, no competitor RNA; lane 2,1 pg of
competitor; lane 3, 5 pg; lane 4, 10 pg; lane 5, 25 pg; lane 6, 50 pg; lane 7,
75 pg; lane 8, 100 pg; lane 9, 250 pg competitor. The 316-bp PCR product
derived from the competitor RNA (B) is readily distinguishable from the 514-
bp product generated from the normal EGP2 mRNA transcript obtained (A).
After densitometry the initial amount of EGP2 mRNA in the MCF-7 sample
was calculated to be 18.9 pg 100 ng-1 total cellular RNA
procedures (Chirgwin et al, 1979). The concentration of recombi-
nant competitor RNA was determined spectrophotometrically.
cDNA synthesis
An aliquot of either 100 ng (for cell lines) or 500 ng (for blood or
bone marrow samples) of total cellular RNA was mixed with
a variable amount of synthetic competitor RNA, ranging from
100 pg to 0.5 fg. To this was added 0.5 ,l of RNAguard
(Pharmacia) and 16.6 ng ofEGP2 REV primer to a final volume of
9 .tl. The EGP2 REV primer, used here as the first-strand primer,
was allowed to anneal at 54°C for 30 min. Subsequently added
were cDNA reaction buffer (Pharmacia), 8 U of MMuLV reverse
transcriptase (Pharmacia) and another 0.5 gl of RNAguard to a
total volume of20 gl. The reaction mixture was incubated at 370C
for 90 min.
Table 1 Mean (+ s.d.) EGP2 expression levels in carcinoma cells lines
calculated from the quantitative RT-PCR assays (n = 3)
Cell line mRNA copy number per cell
GLC-3 650 (130)
GLC-4 No expression detected
GLC-14 150 (40)
Colo 320 15 (5)
MCF-7 1500 (200, n = 6)
plasmid by digestion of the two BamHI sites present within the
EGP2 coding region, at positions 635 and 843. This procedure
excises a 198-bp fragment from the EGP2 cDNA. After religation
the plasmid was designated CDM8 EGP2-B. When subjected to
PCR amplification with EGP2-specific primers (see above),
CDM8 EGP2-B gives rise to a 316-bp product that is readily
distinguishable from the 514-bp product generated from the
normal EGP2 cDNA on a 1.5% agarose gel with ethidium bromide
staining. A schematic outline of the construction procedures and
the expected PCR products is given in Figure lB.
Synthesis of recombinant competitor RNA
All buffers and solutions were made RNAase free by treatment
with DEPC. Recombinant competitor RNA was transcribed in
vitro from the T7 promoter present in the vector located upstream
of the EGP2-B insert, using the Ambion Megascript in vitro
Transcription Kit according to the manufacturer's recommenda-
tions. For synthesis of run-off transcripts of defined size, CDM8
EGP2-B was linearized by digestion with Scal. The resulting
produced blunt ends avoid the generation of unwanted transcripts
observed from 3' overhanging ends. This transcription procedure
gives rise to competitor RNA transcripts of 2015 bp. The cDNA
template was specifically degraded by a 20-min incubation at room
temperature with RNAase-free DNAase I supplied with the tran-
scription kit. DNAase I was then inactivated by heating at 80°C for
5 min. Competitor RNA was subsequently purified using the
caesium chloride centrifugation procedure, according to standard
Polymerase chain reaction conditions
cDNA obtained in the previous step was subjected to 30 PCR
cycles for cell line samples and 40 cycles for blood or bone
marrow samples (denaturing at 94°C for 30 s, annealing at 54°C
for 60s, elongation at 72'C for 90 s) using a DNA thermal cycler
(Perkin ElmerCetus, Norwalk, CT, USA). Before amplification all
samples were subjected to an initial denaturation for 180 s. The
final elongation step was extended by 10 min.
PCR reactions were performed with 0.125 U of Thermus
aquaticus polymerase (Supertaq, HT Biotechnology, Cambridge,
UK), in the reaction buffer supplied by the manufacturer, supple-
mented with 1.75 gM magnesium chloride, 200 ,UM dNTPs, and
300 ng ofboth FW and REV primers.
Optionally, a second-round PCR was performed using the same
set of primers; the reaction products were diluted 1:2 and purified
by phenol-chloroform extraction; 1 tl of the aqueous phase was
used in a subsequent PCR reaction. False-positive signals were
controlled for in this second round by using appropriate positive
and negative controls.
Quantitative RT-PCR procedure
The principle of the transcript titration assay used has been
described previously (Kok et al, 1989; Withoff et al, 1994) and is
schematically outlined in Figure 2.
RESULTS
Quantitative RT-PCR procedure
The results of a representative EGP2 quantitative RT-PCR assay
are shown in Figure 3. An experiment is shown in which a titration
series of competitor RNA solutions, ranging from 1 pg to 250 pg,
is mixed with 100 ng of total cellular RNA from the EGP2-
positive cell line MCF-7. After RT-PCR all subsequent reaction
products of the titration series were analysed by gel elec-
trophoresis (Figure 3, lanes 3-9). A 316-bp product derived from
the competitor RNA was readily distinguishable from the 514-bp
product generated from the normal EGP2 mRNA transcript. After
densitometry, lane 6 wasjudged to display a relative intensity ratio
of 1:1 for both bands. Consequently, this lane was used to quantify
the initial amount of EGP2 mRNA in the sample, which was
calculated to be 18.9 pg 100 ng-I total RNA.
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Figure 4 Sensitivity of the EGP2 RT-PCR assay. The sensitivity of the assay
was assessed by seeding peripheral blood with MCF-7 cells. After two
rounds of PCR, ten MCF-7 cells in 1.0 x 106 leukocytes could still be
visualized (lane 5). Lane M, molecular weight marker (DNA molecular weight
marker VI, Boehringer Mannheim); lane 1, leucocytes; lane 2,1 MCF-7
cells/1.0 x 106 leucocytes; lane 3, 5 MCF-7 cells / 1.0 x 106 leucocytes; lane
4,10 MCF-7 cells/1.0 x 106 leucocytes; lane 5,100 MCF-7, cells/1.0 x 106
leucocytes; lane 6, MCF-7 (positive control); lane 7, GLC4 (negative control);
lane 8, competitor; lane 9, water blank
EGP2 expression in bone marrow and peripheral stem
cell harvests
A bone marrow sample obtained from one of the seven healthy
volunteers (see above) and three additional bone marrow samples
obtained from patients with various haematological malignancies
were analysed by both immunocytochemistry and the competitive
RT-PCR assay. All the bone marrow samples proved to be negative
in immunocytochemistry with the anti-EGP2 MAb MOC3 1.
However, the EGP2 RT-PCR assay demonstrated a distinct 514-bp
band of various intensity in all bone marrow samples analysed.
Calculating from quantitative RT-PCR data, the expression of
EGP2 in bone marrow appears to be very low, i.e. between 1 and
10 pg 5.0 ,ug-I of total cellular RNA. The identity of the detected
band as a specific EGP2 PCR product was established by digestion
with the restriction enzyme BamHI (see BamHI sites depicted in
Figure 1B), which subsequently yielded three DNA fragments of
the expected lengths (data not shown): 262 bp, 198 bp and 54 bp.
Peripheral stem cell harvests from another three patients with
haematological malignancies subjected to EGP2 RT-PCR were
also positive in the PCR assay (data not shown).
EGP2 expression in human carcinoma cell !ines
EGP2 expression was assessed by both immunocytochemistry and
quantitative EGP2 RT-PCR in GLC-3, GLC-4, GLC-14, MCF-7
and Colo 320. All cell lines, except GLC-4, were found to be EGP-
2 positive in both assays. The EGP2 expression levels in these cell
lines calculated from the quantitative RT-PCR assays are given in
Table 1. The calculation ofthe copy numbers per cell is according
to methodology reported previously (Withoff et al, 1994).
Sensitivity of the EGP2 RT-PCR assay
The sensitivity of the assay was assessed by seeding peripheral
blood with MCF-7 cells. The MCF-7 cell line was chosen as it
showed the highest expression of EGP2. After one round of PCR,
ten MCF-7 cells in 1 x 105 leucocytes could still be visualized.
Performing another round of PCR increased sensitivity to ten
MCF-7 cells detectable in 1.0 x 106 PMN cells. The results of the
sensitivity ofthe EGP2 RT-PCR assay are shown in Figure 4.
EGP2 expression in peripheral blood
PBL samples from seven healthy volunteers were analysed for
EGP2 expression by immunocytochemistry using the anti-EGP2
MAb MOC31. From each volunteer at least two slides, approxi-
mately 4 x 104 cells, were inspected. All seven samples were found
to be negative. This observation was verified by performing two
successive rounds of PCR with the EGP2-specific primers
performed on total cellular RNA isolated from the same PBL
samples. Again, using this assay no PCR product could be detected
upon gel electrophoresis. Furthermore, the B-cell, T-cell and
monocyte fractions, isolated by Ficoll-Hypaque from a pool of
buffy coats, all proved to be EGP-2 negative in both immunocyto-
chemistry with MAb MOC31 and the EGP2 RT-PCR assay (two
rounds ofamplification). Total cellular RNA isolated from GLC-3
was used as a positive control, whereas RNA isolated from GLC-4
was used as a negative control (data not shown).
DISCUSSION
The prognosis of patients with malignant tumours deteriorates
with metastatic spread of disease. As therapeutic measures vary,
correct assessment of tumour stage is essential clinical informa-
tion. Commonly, the detection of carcinoma cells in the bone
marrow and peripheral blood is based on morphology or on the
immunological demonstration of proteins specific for epithelia or
tissues using MAbs against the corresponding antigens, e.g. MAb
MOC31 directed against the pancarcinoma-associated glyco-
protein 2 (EGP-2) (Myklebust et al, 1991; Beiske et al, 1992;
Myklebust et al, 1993a, b). The pancarcinoma-associated glyco-
protein EGP2 is expressed in most epithelium-derived carcinomas
and, as no expression of EGP-2 has been found in the peripheral
blood ofbone marrow using anti-EGP2 MAbs (Pantel et al, 1993),
it was considered useful as a tumour marker for circulating tumour
cells and bone marrow involvement. Thus, we assessed the possi-
bility or detecting EGP-2-expressing cells (i.e. tumour cells) at the
mRNA level by means of the sensitive polymerase chain reaction
(RT-PCR). For a reliable estimation ofthe number of tumour cells
involved, we measured the actual number of EGP2 mRNA tran-
scripts using an intemal recombinant competitor RNA standard
with known concentration that is both reversely transcribed and
co-amplified in the same reaction.
In this study we show that amplification by PCR with EGP2-
specific primers on total cellular RNA isolated from the peripheral
blood cell fraction of seven healthy volunteers was negative for
EGP2 expression. Also, in isolatedlymphocytes and monocytes no
signal could be detected. The sensitivity ofthe assay was assessed
by seeding peripheral blood with MCF-7 cells. After two rounds of
PCR a minimum of ten MCF-7 cells in 1.0 x 106 leucocytes could
be detected. This compares with techniques that rely on staining
with MAbs when double-labelling techniques are used. Usually,
the limit of detection with such a technique is one carcinoma cell
per4-5 x 105 mononuclear cells. Data derived from several studies
using RT-PCR techniques to identify carcinoma cells in peripheral
blood samples show that the lower limit ofdetection is ofthe same
order as found in this study (Smith et al, 1991; Matsumura and
Tarin 1992; Mattano et al, 1992; Hardingham et al, 1993; Datta et
British Journal ofCancer (1997) 76(1), 29-35 . Cancer Research Campaign 199734 WHelfrich et al
al, 1994; Gerhard et al, 1994; Israeli et al, 1994; Seiden et al, 1994;
Burchill et al, 1995; Peter et al, 1995).
Currently, the power ofPCR technology seems to limit its use in
clinical practice as it has been found that PCR methods can detect
promiscuous transcription (Chelly et al, 1989; Sarkar and Sommer,
1989) of so-called tissue-specific genes. For example, PGP-9.5
(Norris et al, 1994), prostate-specific antigen (Smith et al, 1995),
cytokeratin 19 (Krismann et al, 1995) and tyrosinase transcripts
(Foss et al, 1995) can be amplified from peripheral blood of
healthy volunteers. Illegitimate transcription ofEGP2 may also be
the explanation of the positive results obtained by us in bone
marrow and peripheral stem cell harvests of patients suffering
from various haematological malignancies. Alternatively, as
staining with MAbs recognizing EGP2 is consistently negative in
the bone marrow, it may be that EGP2 gene translation in the
marrow results in a protein per cell level that is 'below the detection
level ofMAbs.
The quantitative approach described here may be able to deal
with this problem as it enables us to define quantitatively an upper
level of 'normal', namely illegitimate, transcription.
As it is logical to assume that the number ofcirculating tumour
cells is an important parameter for patient outcome, a quantitative
RT-PCR has obvious advantages. However, the results shown here
indicate that considerable variation exists between tumour types as
MCF-7 cells had a 100-fold higher EGP2 expression on level per
cell than Colo 320 cells. Thus, the sensitivity of our assay might
vary between and within different tumour types in vitro. Whether
this phenomenon is present in vivo is not known. Should this
prove to be the case, the copy number of EGP2 mRNA in cells of
the primary tumour would have to be assessed before quantifica-
tion ofcarcinoma cells in peripheral blood could be established.
In conclusion, we have developed a specific and sensitive quan-
titative RT-PCR assay to detect epithelium-derived carcinoma
cells in peripheral blood. In bone marrow and peripheral stem
cells, an unknown population of cells appears to express EGP2
mRNA, which makes this assay problematic for these specimens.
The ability to detect very small numbers of carcinoma cells in the
blood may provide the clinician with an important predictive tool
with respect to recurrence and might help in a better selection for
adjuvant therapy.
ABBREVIATIONS
EGP-2, epithelial glycoprotein-2; MAb, monoclonal antibody;
cDNA, complementary DNA; SCLC, small cell lung carcinoma;
FCS, fetal calf serum; BSA, bovine serum albumin; bp, basepairs;
kb, kilobasepairs; DEPC, diethylpyrocarbonate; PBS, phosphate-
buffered saline (9.0 mM disodium hydrogen phosphate, 1.3 mM
sodium dihydrogen phosphate, 140 mm sodium chloride, pH 7.2);
RT-PCR, reverse transcriptase polymerase chain reaction; PBL,
peripheral blood lymphocytes.
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